1 **Polygenic risk for Alzheimer's disease predicts sleep slow-waves and daytime**
2 **sleepiness in youth**

3
4 Short title: **Linking Alzheimer's disease to sleep in youth**
5

Vincenzo Muto[1,2#], Ekaterina Koshmanova[1#], Pouya Ghaemmaghami[1#], Mathieu Jaspar[1,2,3],
Christelle Meyer[1,2], Mahmoud Elansary[4], Maxime Van Egroo[1], Daphne Chylinski[1], Christian
Berthomier[5], Marie Brandewinder[5], Charlotte Mouraux[1], Christina Schmidt[1,2], Grégory
Hammad[1], Wouter Coppieters[4], Naima Ahariz[4], Christian Degueldre[1], André Luxen[1], Eric
Salmon[1,3,6], Christophe Phillips[1,7], Simon N. Archer[8], Loic Yengo[10], Enda Byrne[10], Fabienne
Collette[1,3], Michel Georges[4], Derk-Jan Dijk[8,9], Pierre Maquet[1,2,6], Peter M. Visscher[10], Gilles
Vandewalle[1]*
13

Affiliations:

[1] GIGA-Cyclotron Research Centre-In Vivo Imaging, University of Liège, Liège, Belgium.
[2] Walloon Excellence in Life sciences and Biotechnology (WELBIO, Belgium).
[3] Psychology and Cognitive Neuroscience Research Unit, University of Liège, Liège, Belgium.
[4] GIGA-Medical Genomics, University of Liège, Liège, Belgium.
[5] Physip, Paris, France.
[6] Department of Neurology, University Hospital of Liège, Liège, Belgium.
[7] GIGA-In Silico Medicine, University of Liège, Liège, Belgium.
[8] Sleep Research Centre University of Surrey, University of Surrey, Guildford.
[9] UK Dementia Research Institute.
[10] Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
25

26 [#] These authors contributed equally to this work
27

28 * Correspondence to: Gilles Vandewalle, GIGA-Cyclotron Research Centre-In Vivo Imaging,
29 Bâtiment B30, Allée du 6 Août, 8, 4000 Liège, Belgium, +3243662316,
30 gilles.vandewalle@uliege.be

31
32

Abstract

A bidirectional detrimental relationship between sleep alteration and Alzheimer's disease (AD) has been reported in cognitively normal older adults. Here, we tested whether a similar association could be detected in young adults, decades before typical AD symptom onset. We investigated associations between sleep endophenotypes and genome-wide Polygenic Risk Scores (PRS) for AD in 363 young men (22.1±2.7y) devoid of sleep and cognitive disorders. AD PRS was associated with higher slow wave energy, a marker of sleep need, during habitual sleep and following sleep loss, and, potentially, with the relative increase in slow wave energy following sleep deprivation, reflecting sleep homeostasis. Furthermore high AD PRS was correlated with higher daytime sleepiness. These results imply that sleep features may be associated with AD liability in young adults and suggest that, contrary to older adults, denser and/or more intense sleep slow waves are associated with AD risk in early adulthood.

Introduction

Defective proteostasis of brain amyloid-beta (Aβ) and tau protein antedates the clinical manifestations of Alzheimer's disease by decades (Jack et al., 2018; Musiek and Holtzman, 2015; Scheltens et al., 2016). This so-called "preclinical" window constitutes an opportunity for internvention that would hopefully reduce the predicted increase in AD prevalence (Norton et al., 2014), despite the absence of disease modifying treatments in the foreseeable future. In this respect, the further identification of AD risk factors is of paramount importance.

Altered sleep has recently been related to increased risk for AD, over and above sleep disturbances in AD patients (Van Egroo et al., 2019). Longer latency to fall asleep and reduced sleep slow waves and rapid eye movement (REM) sleep are associated with both Aβ plaques and Tau neurofibrillary tangles (NFTs) in cognitively normal participants (Branger et al., 2016; Lucey et al., 2019; Mander et al., 2015). Sleep fragmentation and the reduction in REM sleep quantity in cognitively normal individuals aged >60 y predict the future risk of developing AD (Lim et al., 2013; Pase et al., 2017). Acute sleep deprivation (Holth et al., 2019; Ooms et al., 2014), and experimentally induced reduction of sleep slow waves (Ju et al., 2017), increases cerebrospinal fluid (CSF) Aβ and Tau protein content.

In *post mortem* human brain tissues, the first signs of brain protein aggregation are identified in the locus coeruleus (LC), a brainstem nucleus essential to sleep regulation (Mather and Harley, 2016), under the form of pretangles, consisting of phosphorylated Tau protein (Braak and Del Tredici, 2011). Critically, LC pretangles can be detected during adolescence, while by age 30, they can be detected in the majority of the population (> 90%) (Braak and Del Tredici, 2011). With age, Tau deposits increase in the brain in a stereotypical manner and are tightly associated with cognitive decline in overt 'clinical' AD (Braak and Del Tredici, 2011). Individual variations in these intrinsic properties should be reflected in brain

function, including sleep, whether or not Tau aggregation has already occurred. Furthermore,

although the consequences of LC pretangles are unknown (Mather and Harley, 2016), they

might affect brain functions, including during sleep. Tau plays an important role in synaptic

function while Tau pretangles and their surrounding soluble hyperphosphorylated Tau, which

remain undetectable *in vivo* in humans, are suspected to have a deleterious impact on

neuronal function (DeVos et al., 2013; Hall et al., 2015; Mondragón-Rodríguez et al., 2012;

Pooler et al., 2014; Schultz et al., 2018).

We therefore reasoned that early associations between sleep and AD might exist in

young healthy adults (i.e., before 30 y), especially because AD is heritable (Marioni et al.,

2018). Sporadic AD, the most common form of AD in the general population, has an estimated

heritability ranging between 58% to 79% (Ertekin-Taner, 2010; Gatz et al., 2006). Individual

Polygenic Risk Scores (PRS) for AD can be computed based on results of published Genome

Wide Association Studies (GWAS). These PRS reflect part of the genetic liability for AD in any

asymptomatic individual and, at the group level, can be associated with phenotypes of interest

which are related to the (risk) pathways leading to AD (Euesden et al., 2015; Ge et al., 2019).

Recent studies reported significant association between AD PRS and CSF Aβ content

(Martiskainen et al., 2015), cortical thickness (Sabuncu et al., 2012), memory decline (Marden

et al., 2016), and hippocampus volume (Mormino et al., 2016) in cognitively normal older

adults (> 45 y) but, importantly, also in young adults (18 -35 y) (Mormino et al., 2016).

Here, we conducted a proof-of-concept study to establish that sleep can be related to

AD risk in young adults, using PRS for AD. We phenotyped sleep under different conditions

(baseline, sleep extension, recovery sleep after total sleep deprivation) in a homogenous

sample of young healthy cognitively normal men without sleep disorders and computed

individual PRS for AD. We hypothesized that high PRS would be associated with sleep metrics

that had previously been associated with AD features in cognitively normal older adults. We

further explored whether subjective assessments and behavioural correlates of sleep quality

would be associated with PRS for AD.

Results

Following 3 weeks of imposed regular sleep which was confirmed with actimetry, 363 healthy

men aged between 18 and 31 y (**Table 1**) completed a 7-day protocol including

polysomnographically recorded sleep during habitual sleep-wake times (range of total sleep

duration: 361 to 518 min), during a 12h extended sleep opportunity, and during a 12h recovery

sleep opportunity following 40h of total sleep deprivation (**Figure 1**). A blood sample was

collected in all participants to assess whole genome common single nucleotide

polymorphisms (SNPs). PRS were computed as the weighted sum of the effect sizes of the AD-

associated SNPs, obtained from summary statistics of AD cases vs. controls GWAS (Euesden

et al., 2015; Ge et al., 2019). PRS can indicate the presence of a genetic signal in moderate

sample size studies (Euesden et al., 2015; Sabuncu et al., 2012) as long as it is computed based

on a very large GWAS (Dudbridge, 2013; Santoro et al., 2018). We therefore used the summary

statistics of one of the largest AD-GWAS available to date (N = 388,324) (Marioni et al., 2018)

to compute individual PRS for AD in our sample and related these to sleep EEG characteristics

following multiple quality control steps (**Supplementary Figure S1**).

Polygenic risk for AD is associated with the generation of slow waves during sleep

We first focused on baseline sleep, as it is most representative of habitual sleep, to evaluate

sleep metrics that might be associated with AD liability. Given our sample size, we reduced

the multiple comparison burden by selecting *a priori* variables of interest among

electrophysiology sleep metrics that have previously been related to Aβ and Tau in cognitively

normal older adults: sleep onset latency [SOL] (Branger et al., 2016; Ettore et al., 2019),

duration of wakefulness after sleep onset [WASO] (Ettore et al., 2019), duration of REM sleep

(Pase et al., 2017), slow wave energy [SWE] during NREM sleep (Lucey et al., 2019; Mander et

al., 2015), i.e. the cumulated power in the 0.5-4 Hz EEG band, and hourly rate of micro-arousal

during sleep (Ju et al., 2017). To compute PRS, one considers SNPs below a p-value threshold

in the reference GWAS; the optimal threshold for SNP selection to best compute a PRS for AD

is not established. Previous studies employed very exclusive GWAS p-values ($p \sim 10^{-8}$) (Sleegers

et al., 2015) to more inclusive p-values (p = .5) (Escott-Price et al., 2015; Mormino et al., 2016),

leading to the inclusion of effect sizes of a few tens to hundreds of thousands SNPs to compute

AD PRS. We opted for computing PRS based on increasingly inclusive p-value thresholds

(including SNPs reaching GWAS significance – $p < 5 \times 10^{-8}$ - to very liberal p < 1), whilst also

pruning SNPs based on their correlation structure (i.e. linkage disequilibrium) (**Supplementary**

Table S1) (Escott-Price et al., 2015; Mormino et al., 2016). In addition, we performed a PRS

analysis using all SNPs without any selection.

General linear model (GLM) analyses controlling for age, body mass index (BMI) and

total sleep time (TST), reveal an significant association between baseline night SWE and AD

PRS (p <0.02; **β ≥ 0.12**) from a p-value threshold of p=0.05 up to selecting all SNPs; the

association reached stringent experiment-wise correction for multiple comparisons when

selecting all SNPs (p < 0.00125, see methods; **β = 0.17**; **Figure 2A; Supplementary Table S2**).

We performed a negative control analysis using a PRS for height, a variable for which no

association with sleep metrics was expected, and found no association (**Supplementary Figure**

S2A). The association between AD PRS and SWE was positive (**Figure 2B**) indicating that higher

SWE was associated with higher AD-PRS. SWE was also positively associated with TST

(**Supplementary Table S2**), which was expected since TST conditions the opportunity to generate slow waves, and negatively with age, which is in line with the literature (Carrier et al., 2011) but may still be surprising given the young age of our sample. Importantly, since GLM included TST and age, they are not driving the association we find between SWE and PRS for AD.

Sleep onset latency (SOL) also reached significant association with AD PRS from a p-value threshold of p=0.05 up to p = 1 (p ≤ 0.04; **β = -0.11**), but significance did not reach stringent experiment-wise correction for multiple comparisons (p < 0.00125) (**Figure 2A; Supplementary Table S2**). Hence, this result has to be considered with caution and will not be extensively commented upon. It is interesting to note, however, that the association between PRS for AD and SOL is negative, with higher PRS associating with shorter sleep latency (**Figure 2C**). Of note, REM% reached uncorrected significance (p < 0.05) for thresholding at p=0.05 (**β = 0.1**), with a positive association with AD PRS (**Figure 2A; Supplementary Table S2**), but, since it is observed for only one p-value threshold, this will not be discussed any further.

These results indicate that, particularly when considering all SNPs to construct the AD PRS, the overnight power of the slow waves generated during Non-REM sleep, which is a widely accepted measure of sleep need (Dijk and Czeisler, 1995), is linearly and positively associated with AD genetic liability. This finding suggests that individuals with a higher genetic liability for AD have a higher need for sleep. This idea is further reinforced by the fact that association between SWE and AD PRS is also significant when only considering SWE of the first hour of sleep (Dijk and Czeisler, 1995) (**Supplementary Figure S3 & Table S3**), and the potential negative association with SOL, which depends in part on sleep need.

Since slow oscillations (SO), i.e. EEG slow waves < 1 Hz, may be distinct from faster slow waves (Steriade and Amzica, 1998), we further decomposed SWE into SO-SWE (0.5-1Hz) and

faster-oscillations—SWE (FO-SWE; 1.25 – 4 Hz). Both SO-SWE and FO-SWE were similarly and

significantly associated with AD PRS and for the same p-value thresholds (**Figure 2D;**

Supplementary Table S3). The association we found between SWE and AD PRS does not

appear therefore to arise exclusively from either slower or faster slow waves.

Recovery sleep, slow wave sleep rebound and extension night

When considering sleep EEG of the other nights, we only included SWE, as it is the only sleep

metric that was associated with PRS for AD at stringent correction for multiple comparisons

threshold. Similarly to baseline night, when considering SWE during the recovery night that

followed total sleep deprivation, GLM including age, BMI and TST, reveal that SWE and AD PRS

are significantly associated ($p \leq 0.04$; **β ≥ 0.11**) from p-value thresholding at $p=0.1$ up to using

all SNPs (**Figure 3A; Supplementary Table S4**), and the association reached stringent

experiment-wise correction for multiple comparisons at p-value threshold of $p=1$ ($p <$

0.00625). Again, the association was positive with higher SWE associated with higher AD PRS

(**Figure 3B**) and results were similar when considering only SWE of the first hour of sleep

(**Supplementary Figure S3 & Table S4**). Individuals typically produce more sleep slow waves

in response to sleep loss, as part of the homeostatic regulation of sleep (Klerman and Dijk,

2005). Therefore, individuals with higher need for sleep after sleep loss have a high PRS for

AD.

Slow wave sleep rebound quantifies the physiological response to a lack of sleep based

on the relative changes from normal sleep to recovery sleep following sleep loss. We

computed the ratio between the initial SWE (1h of sleep) during recuperation and baseline

nights to assess SWE rebound. GLM analysis, including age and BMI, indicated that SWE

rebound reached significant association with AD PRS when including all SNPs (**β = -0.11**), but

significance did not reach stringent experiment-wise correction for multiple comparisons (p <

0.00625) (**Figure 3A; Supplementary Table S4**). Sleep rebound is driven by sleep homeostasis

which tightly regulates sleep duration and intensity based on prior sleep-wake history (Dijk

and Landolt, 2019). Since we observe an association with AD PRS for a single p-value threshold

at uncorrected p-value our findings suggest that, in our sample, AD PRS was not tightly

associated with sleep homeostatic response. Interestingly though, Spearman's correlation

indicated that SWE rebound was correlated to SWE during the recovery night (r = 0.39, p <10^{-14}

; **Figure 3C)**.

We then considered SWE during the extension night and PRS for AD in a GLM, including

age, BMI and TST. Results indicated that extension night SWE was not significantly linked to

AD PRS. This may be because sleep timing for this particular night affects sleep quality (Dijk

and Landolt, 2019; Dijk and Czeisler, 1995) (**Figure 3A**). In contrast to baseline and

recuperation sleep periods which were initiated at habitual sleep time, sleep extension started

2 hours before habitual sleep time, covering the end of a period known as the evening "wake-

maintenance zone" corresponding to the time at which the circadian system maximally

promotes wakefulness (Dijk and Czeisler, 1995). In addition, the circadian system is known to

affect the relative content in Non-REM and REM sleep as well as in different EEG frequencies

(Dijk and Landolt, 2019; Dijk and Czeisler, 1995). Therefore, the imposed 2h advance of sleep

time during the extension night affected sleep quality, which may have reduced the

association between SWE and AD PRS found with baseline and recovery nights.

Polygenic risk for AD is associated with increased subjective daytime sleepiness

We next focused on the non-EEG sleep metrics of our protocol and explored their potential

association with AD PRS. Based on the 3 weeks of actigraphy with imposed regular habitual

sleep time at home, we computed the probability of transition from rest to activity during the

sleep period [kRA; (Lim et al., 2013)]. kRA is a proxy for sleep fragmentation and has been

associated with cognitive decline and the risk for developing AD in cognitively normal older

adults [mean age 81.6 y (Lim et al., 2013)]. kRA showed a negative association (higher AD PRS

is associated with less fragmented sleep) with PRS for AD for two p-value thresholds, p=5 x 10^{-8}

and p = 10^{-8} (**Figure 4A; Supplementary Table S5**), but did not reach stringent experiment-

wise correction for multiple comparisons (p < 0.002); it will not be further discussed.

Two questionnaires assessed habitual subjective sleep quality and daytime sleepiness

before the start of the protocol. Subjective sleep quality was not significantly associated with

AD PRS. By contrast, subjective daytime sleepiness was significantly associated with PRS for

AD (p < 0.05; **β ≥ 0.11**) from thresholding at p < 10^{-4} up to a threshold of p < 1 and at stringent

experiment-wise correction for multiple comparisons at p-value thresholds of p < 0.05 and p

< 0.3 (p < 0.002, see methods; **β ≥ 0.16**; **Figure 4A; Supplementary Table S5**). The association

was positive indicating that higher habitual subjective daytime sleepiness was associated with

higher AD PRS (**Figure 4B**). This shows that the association between AD PRS and sleep need,

as assessed by electrophysiology, is not a mere effect of the protocol and is mirrored at the

behavioural level during habitual daytime functioning (outside the experimental protocol).

Importantly the vast majority of participants had no or mild levels of sleepiness with a minority

(N = 28) reporting moderate level of daytime sleepiness; the association with daytime

sleepiness is therefore not driven by extreme or clinically relevant sleepiness levels but rather

by ordinary variability in healthy young individuals.

236
237

Discussion

We provide evidence that genetic liability for AD is related to sleep characteristics and daytime sleepiness in young adults (aged 18 to 31 y), i.e. decades before typical onset age of clinical AD symptoms and at an age at which current AD biomarkers are typically negative. Our sample size is modest for the detection of small effect size associations, so the present results should be considered as a proof-of-concept for linking AD liability and sleep in young adults. We emphasize, however, that the unique deep phenotyping of our protocol in hundreds of participants, based on gold standard electrophysiology and comprising different sleep conditions, undoubtedly increased the sensitivity of our analyses so that we could find associations that survived stringent correction for multiple comparisons. Importantly, our protocol provides links between disease risk and sleep physiology in contrast to coarser phenotyping based on sleep questionnaires or actimetry alone. The characteristics of our sample renders our findings remarkable: to increase the genetic uniformity of the sample we only included Caucasian men within a narrow age range; they were healthy and devoid of any sleep disorders or sleep complaints and their prior sleep-wake history was recorded and stable. In this carefully selected homogenous sample, higher PRS for AD was associated with producing denser or larger slow waves during baseline and recovery night time sleep, potentially with large slow wave sleep rebound following sleep deprivation, and with reporting higher daytime sleepiness.

Larger and more abundant slow waves during habitual sleep in young and healthy individuals can result from an increased sleep need due to insufficient prior sleep (Klerman and Dijk, 2005). This appears unlikely: prior sleep-wake history was stringently controlled for 3 weeks prior to entering the lab, ruling out undue sleep deprivation, sleep restriction or disrupted rhythmicity. Moreover, throughout the protocol, participants followed their own

sleep schedule, a regime that should not expose them to important chronic sleep restriction.

Finally, SWE during the sleep extension night did not significantly correlate with subjective

daytime sleepiness (Spearman's correlation r = 0.08, p = 0.11), supporting the idea that, when

given a longer sleep opportunity, individuals with higher and yet normal daytime sleepiness

did not sleep more intensely to recover a putative prior sleep debt. Alternatively, increased

slow wave density and/or intensity could reflect a faster build-up of sleep need (Viola et al.,

2007). Indeed, sleep homeostasis is thought to result from molecular and cellular changes

induced by waking brain function and behaviour (Scammell et al., 2017; Tononi and Cirelli,

2014). Synaptic potentiation and increased synaptic strength resulting from waking

experience are reflected in a progressive increased cortical excitability during wakefulness

(Huber et al., 2013; Ly et al., 2016) and an increase in slow wave activity during subsequent

sleep (Scammell et al., 2017; Tononi and Cirelli, 2014). Likewise, extracellular glutamate

concentration and glutamatergic receptor density increase with time awake and affect brain

function (Dash et al., 2009; Hefti et al., 2013). Here, SWE rebound following sleep loss, i.e. the

ratio between baseline and recovery sleep, was only significantly associated with high PRS for

AD for one p-value threshold and at uncorrected significance threshold, but was strongly

associated with SWE during recovery sleep. We therefore find only partial evidence for this

second hypothesis, which will require more investigations.

How are these findings related to AD? The answer to this question remains speculative

because the time course of AD processes across lifespan is still poorly understood. In

transgenic mice, neuronal activity locally increases the level of Aβ in the interstitial fluid and

drives local Aβ aggregation (Bero et al., 2011). The progressive Aβ deposition ultimately

disrupts local functional connectivity and increases regional vulnerability to subsequent Aβ

deposition (Bero et al., 2012). We might thus hypothesize that individuals with more intense

brain activity during wakefulness (and therefore also during sleep) would also be exposed to

larger Aβ extracellular levels and a greater risk of developing Aβ deposits. This hypothesis

appears unlikely for the following reasons. First, post mortem examinations show that the

earliest evidence of Aβ deposits (stage 1 (Thal et al., 2002)) is not observed before 30 y (Braak

and Del Tredici, 2015). Second, Aβ oligomers might be released and exert their detrimental

effect on brain function at an earlier age. However, in transgenic mice, sleep-wakefulness

cycle and diurnal fluctuation in brain extracellular Aβ remain normal until plaque formation

(Roh et al., 2012).

By contrast, given the age range of our population sample, the reported topography of

pretangles at this age (Braak and Del Tredici, 2011) and the power of PRS for AD to

discriminate AD patients in case-control samples (Escott-Price et al., 2015), higher PRS in our

young sample might reflect the influence of incipient Tau aggregation onto sleep regulation

through the LC (and other non-thalamic cortically-projecting nuclei, as raphe nuclei) (Braak

and Del Tredici, 2011). Tau, an intracellular protein, is also detected in the extracellular space.

Over and above a low level constitutive tau secretion (Chai et al., 2012), neuronal activity

increases the release of tau in the extracellular space (Yamada et al., 2014), thereby

participating in enhancing tau spread and tau pathology in vivo (Schultz et al., 2018).

Moreover, early electrophysiological changes indicative of hyperexcitability are observed in

intact neurons from transgenic tau mice (Crimins et al., 2012). In the cerebral cortex of tau

transgenic mice, glutamatergic and GABAergic neurons are in a hypermetabolic state,

characterized by a relative increase in production of glutamate (Nilsen et al., 2013). By

contrast, decreasing tau in epilepsy-prone transgenic mice reduces neuronal hyperexcitability

(Holth et al., 2013). These findings would suggest that a strong cerebral activity during

wakefulness would result in a higher daily average in perceived sleepiness, a substantial tau

release and an enhanced sleep homeostasis processes, as indicated by denser and larger slow

waves.

The reasons for the vulnerability of LC to Tau aggregation are not established but might

reside in its constant recruitment for essential functions, its energy demanding and ubiquitous

brain connections, its high vascularization or its higher susceptibility to oxidative stress

(Mather and Harley, 2016). Although it tantalizing to hypothesize that tau is involved in the

mechanisms linking slow wave sleep and AD liability, one can also speculate that it is the LC

intrinsic characteristics that are related to tau vulnerability (subsequent) that associated with

PRS for AD, meaning that the association would not necessarily require the presence of tau to

be detected.

On the other hand, in tau transgenic mice, misfolded and hyperphosphorylated tau

alters hippocampal synaptic plasticity (Polydoro et al., 2014), eventually induces a loss of

hippocampal LTP and causes reduction of synaptic proteins and dendritic spines (Van der

Jeugd et al., 2012) (Sydow et al., 2011). These findings would predict a lower sleep need in

participants with high AD liability. However, it is possible that these detrimental processes

take place later on in the development of the disease or emerge from an interaction between

tau and Ab (Oddo et al., 2003) (Fein et al., 2008). Accordingly, in older adults, significant

associations, opposite to the current findings, were observed between slow wave sleep and

risk for AD based on PET biomarkers (Lucey et al., 2019; Mander et al., 2015): higher Aβ

(Mander et al., 2015) or tau (Lucey et al., 2019) burdens were associated with lower sleep

slow wave EEG power. Our results suggest therefore that the association between AD risk and

sleep homeostasis changes with age: at an early stage, dense and large slow waves would be

associated with increased AD risk. Later on, the ability to generate slow waves would play a

protective role against AD risk. Deep sleep phenotyping across all ages and/or in long term

longitudinal studies will have to test this hypothesis.

We emphasize that the cross sectional nature of our study, precludes any causal

interpretation of the association we find between AD and sleep. We further stress that our

sample only include men and cannot therefore be extended to the entire population. Women

have been reported to have different sleep characteristics, including the production of more

numerous and intense slow waves during sleep (Svetnik et al., 2017). It is also worth

mentioning that we cannot isolate in our findings the specific contributions of the circadian

timing system, which is the second fundamental mechanism regulating sleep and wakefulness

(Dijk and Landolt, 2019). Although we find significant association between AD PRS and

baseline/recovery SWE and daytime sleepiness across similar p-value thresholds, more

research is also required to determine how many SNPs one has to include, i.e. what SNP

selection strategy should be used to best predict AD. Previous studies support that using a

lenient p-value thresholds is successful in doing so (Escott-Price et al., 2015; Mormino et al.,

2016), thus we are confident that our finding are related to AD liability. Our PRS calculation

was stringently controlled for the weight of chromosome 19 (see methods) to avoid excessive

contribution from Apolipoprotein E (APOE) genotype, which is the genetic trait most

associated with sporadic AD. When comparing APOE ε4 carriers genotype vs. non-carriers, no

significant difference in baseline night SWE and daytime sleepiness was observed

(Supplementary Figure S4), in line with our findings that a large number of SNPs is required

to find an association between SWE and PRS for AD.

The specificity of our findings for a given EEG frequency band and/or for NREM remains

to be fully established. As many previous studies on linking sleep and AD risk [e.g. (Lucey et

al., 2019; Mander et al., 2015)], we only focussed on a limited set of sleep metrics, and

included a single power measure over a given frequency band. Although not the focus of the

present paper, we computed SWE, relative SWE (i.e. ratio between SWE and overnight total

NREM power), overnight cumulated total power during NREM sleep and overnight cumulated

power in the 2 to 6 Hz band during REM sleep of the baseline night in individuals among the

higher and lower AD PRS quartile **(Supplementary Figure S5)**. This simple analyses indicates

that individuals with 25% highest AD PRS had higher power than individuals with 25% lowest

AD PRS for all three absolute measures (t-test; $p ≤ 0.01$ but not for relative SWE ($p = 0.14$),

suggesting that our findings may not be specific to NREM sleep and SWE. We emphasize,

however, that, given our modest sample size, our analyses was not planned to address such

question. This first preliminary analysis warrants future studies with larger sample size

ensuring sufficient power when using a larger set of sleep metrics. Since we also find that

daytime sleepiness, a wakefulness trait, is associated with PRS for AD, and because of the link

between tau protein and cortical excitability (Holth et al., 2013), neuronal activity synchrony

during wakefulness should be associated with the risk for developing AD to assess whether

isolated links are specific to sleep.

In conclusion, we find that denser and/or more intense sleep slow waves during

baseline and recovery sleep and daytime sleepiness are associated with the genetic liability

for AD in young and healthy young men. This finding supports that sleep slow wave and

sleepiness measures may help early detection of an increased risk for AD and reinforce the

idea that sleep may be an efficient intervention target for AD. Similarly to most studies

associating PRS to phenotypes of interest [e.g. (Marden et al., 2016; Mormino et al., 2016;

Sabuncu et al., 2012; Santoro et al., 2018)], the effects we isolated constitute relatively small

effects ($r < 0.2$), however, recalling that sleep must be envisaged within the multifactorial

aspect of a complex disease such as AD (Norton et al., 2014).

Materials and Methods

Participants

Three hundred and sixty-four young healthy men (aged 18-31 years) were enrolled for the study after giving their written informed consent, and received a financial compensation. This research was approved by the Ethics Committee of the Faculty of Medicine at the University of Liège, Belgium.

Exclusion criteria were as follows: Body Mass Index (BMI) > 27; psychiatric history or severe brain trauma; addiction, chronic medication affecting the central nervous system; smoking, excessive alcohol (> 14 units/week) or caffeine (> 3 cups/day) consumption; shift work in the past year; transmeridian travel in the past three months; moderate to severe subjective depression as measured by the Beck Depression Inventory (BDI)(Beck et al., 1988) (score > 19); poor sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989) (score > 7). Participants with sleep apnea (apnea hypopnea index > 15/hour; 2017 American Academy of Sleep Medicine criteria, version 2.4) were excluded based on an in-lab screening night of polysomnography. One participant, part of a twin pair, was excluded from the analyses so that the analysed sample included 363 participants (**Table 1**). EEG recordings were missing due to technical issues for three of the five participants per nights of sleep considered in this manuscript. No individual had more than one night of sleep missing so that all 363 individuals contributed to at least part of the analyses reported here. The Epworth Sleepiness Scale (Johns, 1991) was used to characterize daytime sleepiness but was not used for inclusion. While most participants scored normal values (≤ 11), 28 participants had scores ranging from 12 to 15, corresponding to moderate daytime sleepiness. Because of an initial error in automatic evaluation of computerized questionnaires, seven participants had PSQI scores higher than cut-off (scores of 8 or 9). No participants were,

however, taking sleep medication. To avoid reducing sensitivity, these participants were

included in all analyses but removing them did not change statistical outcomes.

Although available in our laboratory, Ab- and tau- PET scans were not conducted in

participants: it was felt unethical to expose them to an irradiation while results would

necessarily be normal.

Experimental Protocol

Individual sleep-wake history was strictly controlled: during the three weeks preceding the in-

lab experiment, participants were instructed to follow a regular sleep schedule according to

their habitual sleep timing (+/-30 min for the first 2 weeks; +/- 15 min for the last week).

Actigraphy data showed that included participants faithfully followed the assigned schedules.

Figure 1 provides an overview of the protocol. On Day 1, a urine drug test was

performed (10-multipanel drug) before completing an adaptation night at habitual

sleep/wake schedule during which a full polysomnography was recorded in order to screen

for sleep related breathing disorders or periodic limb movements. On Day 2, participants left

the lab with the instruction not to nap (checked with actigraphy). They returned to the

laboratory at the end of Day 2, completed a baseline night of sleep under EEG monitoring at

habitual sleep/wake schedule and remained in the laboratory until Day 7 under constant

CCTV. A 12h sleep extension night under EEG and centered around habitual sleep mid-point

was initiated on Day 3, in complete darkness with the instruction to try to sleep as much as

possible. Day 4 included a 4h afternoon nap under EEG recording (centred 1h after the mid-

point between morning wake-up time and evening sleep time) further dissipated any residual

sleep need. What we termed the "before" night was also initiated on Day 4. It consisted in 8h

sleep opportunity starting at habitual sleep time. During Day 5 and 6, participants remained

awake for 40 hours under constant routine (CR) conditions [dim light < 5 lux, semi-recumbent

position, 19°C ± 1, regular isocaloric food intake] before initiating a 12h recuperation night

from habitual sleep time until 4h after habitual wake time. Except during sleep (darkness – 0

lux) and constant routine protocol (dim light < 5 lux), participants were maintained in normal

room light levels oscillating between 50 and 1000 lux depending on location and gaze.

Analyses of "before" night, nap and sleep deprivation protocol will be reported elsewhere.

The current study focusses on baseline, extension and recovery nights of sleep.

EEG acquisitions and analyses

Sleep data were acquired using Vamp amplifiers (Brain Products, Germany). The electrode

montage consisted of 10 EEG channels (F3, Fz, F4, C3, Cz, C4, Pz, O1, O2, A1; reference to right

mastoid), 2 bipolar EOGs, 2 bipolar EMGs and 2 bipolar ECGs. Screening night of sleep also

included respiration belts, oximeter and nasal flow, 2 electrodes on one leg, but included only

Fz, C3, Cz, Pz, Oz and A1 channels. EEG data were re-referenced off-line to average mastoids.

Scoring of sleep stages was performed automatically in 30-s epochs using a validated

algorithm (ASEEGA, PHYSIP, Paris, France) (Berthomier et al., 2020) and according to 2017

American Academy of Sleep Medicine criteria, version 2.4. An automatic artefact detection

algorithm with adapting thresholds (Wallant et al., 2016) was further applied on scored data.

Power spectrum was computed for each channel using a Fourier transform on successive 4-s

bins, overlapping by 2-s., resulting in a 0.25 Hz frequency resolution. The night was divided

into 30 min periods, from sleep onset until lights on. For each 30 min period, slow wave energy

(SWE) was computed as the sum of generated power in the delta band (0.5 – 4 Hz range)

during all the NREM 2 (N2) and NREM 3 (N3) epochs of the given period, after adjusting for

the number of N2 and N3 epochs to account for artefacted data (Skorucak et al., 2018). As the

frontal regions are most sensitive to sleep-wake history (Schmidt et al., 2012), SWE was

considered over the frontal electrodes (mean over F3, Fz, F4). To deal with the multiple

comparison issue, we did not consider SWE over the other parts of the scalp (Dijk and Landolt,

2019). Additional analyses also considered cumulative power between 0.5 and 25 Hz during

NREM and cumulative power between 2 to 6 Hz power during REM sleep as well through

similar computation procedures.

Genotyping and Imputation

Blood sample were collected on Day 2 for DNA analyses. The genotyping was performed using

the Infinium OmniExpress-24 BeadChip (Illumina, San Diego, CA) based on Human Build 37

(GRCh37). Missingness of the SNP markers were below 20% in all individuals. Using PLINK

software (Purcell et al., 2007), we excluded the SNPs with a minor allele frequency (MAF)

below 0.01, or Hardy-Weinberg disequilibrium (HWD) significance below 10^{-4}. Markers with

ambiguous alleles (A-T, T-A, G-C, C-G) were excluded as well. We finally ended with 511,729

SNPs. To investigate the relatedness between the individuals, using PLINK --genome

command, we computed the identity by descent (IBD) estimates for all pairs of individuals.

For 8 pairs, the composite pi-hat score was between 0.15 and 0.56 suggesting the existence

of at least 3rd degree relatives in our cohort. However, we did not exclude any individuals at

this level of analysis. We merged our cohort with "1000 Genomes Project" (Altshuler et al.,

2010)and employed principal component analyses (PCA) on the merged samples to see if our

cohort was located in the European cluster (**Figure S1A**). We further assess allele frequencies

coherence of our cohort with the European subset of "1000 Genomes Project" (**Figure S1B**).

Markers with allele frequencies deviating more than 0.2 unit from European allele frequency

were excluded (**Figure S1C**). Genotype imputation was performed using "Sanger imputation

server" by choosing "Haplotype Reference Consortium (release 1.1)" (HRC) as Reference Panel

and the Pre-phasing algorithm EAGLE2. Post-imputation QC was then performed very similarly

to the one of above (MAF < 0.01, HWD < 10^{-4}, imputation quality score < 0.3). As a result of

such filters, 7,554,592 variants remained for the analysis. However, to avoid having markers

with allele frequencies deviating from European allele frequency, we computed the allele

frequencies for the samples in our cohort after imputation and cross checked them with the

European allele frequency (obtained from HRC Reference Consortium (release 1.1)) (**Figure**

S1D). The markers whose allele frequencies were deviating more than 0.2 unit from European

allele frequency were excluded.

Predicting Height

To validate common SNP assessments in our sample we predicted actual height based on

Polygenic Scores computed based on a meta-analysis of a recent GWAS study (Yengo et al.,

2018) on around 700,000 individuals. We used all the variants in the meta-analysis that were

included in our cohort [3121 SNPS out of 3290]. The procedure for calculating the Liability for

height is the same as the one described in the following section. **Figures S1E** visualize the

Pearson correlation results between the actual values for Height and estimated genetic

Liability of Height ($r = 0.46$, $p = 10^{-20}$). Explained variance is very close to that reported

previously (Yengo et al., 2018), i.e. is 24.6% .

Polygenic Risk Score (PRS)

Polygenic risk score (PRS) is defined as the sum of multiple single-nucleotide polymorphism

alleles associated with the trait for an individual, weighted by the estimated effect sizes

(Euesden et al., 2015; Ge et al., 2019). We used the estimated effect sizes from a GWAS by

Marioni et al. including 388,324 individuals, with 67,614 cases - patients and self-report

familial history of AD – and 320,710 controls (Marioni et al., 2018). To generate a set of

approximately independent SNPs in our sample, linkage disequlibrium (LD) clumping was

performed using PLINK (Purcell et al., 2007) on window size of 1000-kb using a pairwise r^2 cut-

off of 0.2 and a predetermined significance thresholds (p-value < 5 10^{-8}, 10^{-6}, 10^{-4}, 0.001, 0.01,

0.05, 0.1, 0.3, 0.5, and 1). Due to the effect of APOE in chromosome 19, we used a more

stringent criteria pairwise r^2 cut-off of 0.01 for this chromosome. In addition, we also

calculated the PRS using all the variants with no pruning, i.e. no correction for linkage

disequilibrium, thereby selecting all SNPs for PRS construction. This procedure yielded a

quantitative polygenic score, under each significance threshold, for each individual in our

cohort.

Height as a negative control

From the known and hypothesised biology, we did not expect any a priori association between

the sleep phenotypes and a genetic liability for height. Therefore, we included an analysis of

polygenic scores for height as a negative control, performing exactly the same association

analyses as we did for liability to AD.

Actigraphy data collection and analysis

Actigraphy data were collected with Actiwatch 4 devices (Cambridge Neurotechnology ltd, UK)

worn on the non-dominant arm. Data consisted in the sum of activity counts over 60-second

intervals. Data were analyzed with *pyActigraphy* (Version v0.1) (Hammad and Reyt, 2019) which

implements the computation of state transition probabilities from rest to activity (kRA) (Lim

et al., 2013). In order to better reflect sleep fragmentation, this probability was calculated only

over sleep periods for each study's participant. The sleep period is defined as the period

comprised between the activity offset and onset times, derived from the average 24h activity

profile. In addition, to mitigate the uncertainty on their exact timing, the offset and onset

times were shifted by +15 min and -15min, respectively.

Statistical Analysis

We employed general linear model (GLM) to test the associations between sleep metrics of

interests as a dependent variable and the estimated PRS as an independent variables and age,

BMI and TST as covariates. Prior to the analysis, we removed the outliers among the sleep

metrics by excluding the samples lying beyond 4 times the standard deviation (the final

number of individuals included in each analyses is reported below each dependent variable in

the supplementary tables). All analyses were performed in Python.

In this study, we analysed multiple traits and multiple polygenic risk scores (PRS) for

association. To control the experiment-wise false positive rate, we estimated the number of

independent tests that we performed, and set an experiment-wise p-value threshold

accordingly. Since the traits are phenotypically correlated with each other and the PRSs are

also correlated, we used the correlation structure to estimate the equivalent number of tests,

which is the number of independent tests that would result in the same overall observed

variation.

For each correlation matrix of traits and PRS, we performed a singular value

decomposition (SVD), ordered the resulting eigenvalues and calculated the sum of all

eigenvalues. We then calculated the minimum number of linear combination of the traits that

resulted in 99% of the variation. For the 5 EEG phenotypic sleep traits this estimate was 5,

showing that they are not highly correlated. Likewise, for the 3 non-EEG phenotypic sleep

traits this estimate was 3. For the 11 PRS for AD and height, the resulting number was 8 and

4, respectively, consistent with a higher correlation structure among the multiple height

predictors. Therefore, our analyses with the 5 EEG sleep metrics implies a total number of 40

and 20 tests when confronted to AD-PRS and height-PRS respectively. Hence, for any of our

trait-PRS combination to be statistically significant when taken multiple testing into account,

the p-value threshold are 0.00125 and 0.0025 for AD and height, respectively. Similarly, our

analyses with SWE in recovery and extension nights and with SWE rebound, each imply 8 tests

and a p-value threshold of p = 0.00625, while our analyses with 3 non-EEG sleep metrics 24

tests and a p-value threshold of p = 0.0021. Additional analyses compared lower and higher

PRS quartile (i.e. 90 individuals with lowest AD PRS and 90 individuals with highest PRS; cf. Fig.

S4) as well as APOE ε4 carriers vs. non carriers (cf. Fig. S5). For these analyses, groups were

compared through t-tests.

Acknowledgments

We thank E. Balteau, C. Borsu, N. Cai, A. Claes, G. Gaggioni, A. Gobalek, B. Herbillon, P.

Hawotte, E. Lambot, B. Lauricella, M. Lennertz, J.Q.L. Ly, M. Micho, G. Salmon and A. Shaffii-

Le Bourdiec for their help in different steps of the study.

Funding

P.G., M.V., C.S., F.C., C.P. and G.V. are supported by the Fonds de la Recherche Scientifique -

FNRS-Belgium. The study was supported by the Wallonia-Brussels Federation (Actions de

Recherche Concertées - ARC - 09/14-03), WELBIO/Walloon Excellence in Life Sciences and

Biotechnology Grant (WELBIO-CR-2010-06E), FNRS-Belgium (FRS-FNRS, F.4513.17 &

T.0242.19 & 3.4516.11), University of Liège (ULiège), Fondation Simone et Pierre Clerdent,

European Regional Development Fund (Radiomed project), Fonds Léon Fredericq. DJD is

supported by the UK Dementia Research Institute (DRI).

Competing interests

All authors declare no competing interests.

Author contributions

Study concept and design: V.M., S.N.A., M.G., D.J.D., P.M., P.M.V. and G.V. Data acquisition:

V.M., M.J., C.Me. Data analyses: V.M., E.K., P.G., C.B., M.B., W.C., N.A. and G.V. Interpretation:

V.M., E.K., P.G., D.J.D., P.M., P.M.V., G.V. Analyses support: E.S., A.L., C.P., L.Y., E.B., M.E., M.V.,

D.C., C.Mo., G.H., C.D., F.C., M.G., C.S. Manuscript draft: V.M., E.K., P.G., D.J.D., P.M., P.M.V.,

G.V. Revised manuscript: all authors.

574
575
References

Altshuler DL, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, Clark AG, Collins FS, De La Vega FM,

Donnelly P, Egholm M, Flicek P, Gabriel SB, Gibbs RA, Knoppers BM, Lander ES, Lehrach H, Mardis

ER, McVean GA, Nickerson DA, Peltonen L, Schafer AJ, Sherry ST, Wang Jun, Wilson RK, Deiros D,

Metzker M, Muzny D, Reid J, Wheeler D, Wang SJ, Li J, Jian M, Li G, Li R, Liang H, Tian G, Wang B,

Wang Jian, Wang W, Yang H, Zhang X, Zheng Huisong, Ambrogio L, Bloom T, Cibulskis K, Fennell

TJ, Jaffe DB, Shefler E, Sougnez CL, Bentley IDR, Gormley N, Humphray S, Kingsbury Z, Koko-

Gonzales P, Stone J, Mc Kernan KJ, Costa GL, Ichikawa JK, Lee CC, Sudbrak R, Borodina TA, Dahl

A, Davydov AN, Marquardt P, Mertes F, Nietfeld W, Rosenstiel P, Schreiber S, Soldatov A V.,

Timmermann B, Tolzmann M, Affourtit J, Ashworth D, Attiya S, Bachorski M, Buglione E, Burke A,

Caprio A, Celone C, Clark S, Conners D, Desany B, Gu L, Guccione L, Kao K, Kebbel A, Knowlton J,

Labrecque M, McDade L, Mealmaker C, Minderman M, Nawrocki A, Niazi F, Pareja K, Ramenani

R, Riches D, Song W, Turcotte C, Wang S, Dooling D, Fulton L, Fulton R, Weinstock G, Burton J,

Carter DM, Churcher C, Coffey Alison, Cox A, Palotie A, Quail M, Skelly T, Stalker J, Swerdlow HP,

Turner D, De Witte A, Giles S, Bainbridge M, Challis D, Sabo A, Yu F, Yu J, Fang X, Guo X, Li Yingrui,

Luo R, Tai S, Wu H, Zheng Hancheng, Zheng X, Zhou Y, Marth GT, Garrison EP, Huang W, Indap A,

Kural D, Lee WP, Leong WF, Quinlan AR, Stewart C, Stromberg MP, Ward AN, Wu J, Lee C, Mills

RE, Shi X, Daly MJ, DePristo MA, Ball AD, Banks E, Browning BL, Garimella K V., Grossman SR,

Handsaker RE, Hanna M, Hartl C, Kernytsky AM, Korn JM, Li H, Maguire JR, McKenna A, Nemesh

JC, Philippakis AA, Poplin RE, Price A, Rivas MA, Sabeti PC, Schaffner SF, Shlyakhter IA, Cooper DN,

Ball E V., Mort M, Phillips AD, Stenson PD, Sebat J, Makarov V, Ye Kenny, Yoon SC, Bustamante

CD, Boyko A, Degenhardt J, Gravel S, Gutenkunst RN, Kaganovich M, Keinan A, Lacroute P, Ma X,

Reynolds A, Clarke L, Cunningham F, Herrero J, Keenen S, Kulesha E, Leinonen R, McLaren WM,

Radhakrishnan R, Smith RE, Zalunin V, Korbel JO, Stütz AM, Humphray IS, Bauer M, Cheetham RK,

Cox T, Eberle M, James T, Kahn S, Murray L, Ye Kai, Fu Y, Hyland FCL, Manning JM, Stephen FM,

Peckham HE, Sakarya O, Sun YA, Tsung EF, Mark AB, Konkel MK, Walker JA, Albrecht MW,

Amstislavskiy VS, Herwig R, Parkhomchuk D V., Agarwala R, Khouri HM, Morgulis AO, Paschall JE, Phan LD, Rotmistrovsky KE, Sanders RD, Shumway MF, Xiao C, Gil AM, Auton A, Iqbal Z, Lunter G, Marchini JL, Moutsianas L, Myers S, Tumian A, Knight J, Winer R, Craig DW, Beckstrom-Sternberg SM, Christoforides A, Kurdoglu AA, Pearson J V., Sinari SA, Tembe WD, Haussler D, Hinrichs AS, Katzman SJ, Kern A, Kuhn RM, Przeworski M, Hernandez RD, Howie B, Kelley JL, Melton SC, Li Yun, Anderson P, Blackwell T, Chen W, Cookson WO, Ding J, Kang HM, Lathrop M, Liang L, Moffatt MF, Scheet P, Sidore C, Snyder Matthew, Zhan X, Zöllner S, Awadalla P, Casals F, Idaghdour Y, Keebler J, Stone EA, Zilversmit M, Jorde L, Xing J, Eichler EE, Aksay G, Alkan C, Hajirasouliha I, Hormozdiari F, Kidd JM, CenkSahinalp S, Sudmant PH, Chen K, Chinwalla A, Ding L, Koboldt DC, McLellan MD, Wallis JW, Wendl MC, Zhang Q, Albers CA, Ayub Q, Balasubramaniam S, Barrett JC, Chen Y, Conrad DF, Danecek P, Dermitzakis ET, Hu M, Huang N, Matt EH, Jin H, Jostins L, Keane TM, Quang Le S, Lindsay S, Long Q, MacArthur DG, Montgomery SB, Parts L, Chris Tyler-Smith, Walter K, Zhang Y, Gerstein MB, Snyder Michael, Abyzov A, Balasubramanian S, Bjornson R, Grubert F, Habegger L, Haraksingh R, Khurana E, Lam HYK, Leng J, Mu XJ, Urban AE, Zhang Z, McCarroll SA, Zheng-Bradley X, Batzer MA, Hurles ME, Du J, Jee J, Coafra C, Dinh H, Kovar C, Lee S, Nazareth L, Wilkinson J, Coffey Allison, Scott C, Tyler-Smith C, Gharani N, Kaye JS, Kent A, Li T, McGuire AL, Ossorio PN, Rotimi CN, Su Y, Toji LH, Felsenfeld AL, McEwen JE, Abdallah A, Juenger CR, Clemm NC, Duncanson A, Green ED, Guyer MS, Peterson JL. 2010. A map of human genome variation from population-scale sequencing. *Nature* **467**:1061–1073. doi:10.1038/nature09534

Beck AT, Steer RA, G. GM. 1988. Psychometric Properties of the Beck Depression Inventory: Twenty-five years of evaluation. *Clin Psychol Rev* **8**:77–100. doi:https://doi.org/10.1016/0272-7358(88)90050-5

Bero AW, Bauer AQ, Stewart FR, White BR, Cirrito JR, Raichle ME, Culver JP, Holtzman DM. 2012. Bidirectional relationship between functional connectivity and amyloid-β deposition in mouse brain. *J Neurosci* **32**:4334–4340. doi:10.1523/JNEUROSCI.5845-11.2012

Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. 2011. Neuronal activity regulates the regional vulnerability to amyloid-ß deposition. *Nat Neurosci* **14**:750–756. doi:10.1038/nn.2801

Berthomier C, Muto V, Schmidt C, Vandewalle G, Jaspar M, Devillers J, Gaggioni G, Chellappa SL, Meyer C, Phillips C, Salmon E, Berthomier P, Prado J, Benoit O, Bouet R, Brandewinder M, Mattout J, Maquet P. 2020. Exploring scoring methods for research studies : Accuracy and variability of visual and automated sleep scoring 1–11. doi:10.1111/jsr.12994

Braak H, Del Tredici K. 2015. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. *Brain* **138**:2814–2833. doi:10.1093/brain/awv236

Braak H, Del Tredici K. 2011. The pathological process underlying Alzheimer's disease in individuals

under thirty. *Acta Neuropathol* **121**:171–181. doi:10.1007/s00401-010-0789-4

Branger P, Arenaza-Urquijo EM, Tomadesso C, Mézenge F, André C, de Flores R, Mutlu J, de La Sayette

V, Eustache F, Chételat G, Rauchs G. 2016. Relationships between sleep quality and brain volume,

metabolism, and amyloid deposition in late adulthood. *Neurobiol Aging* **41**:107–114.

doi:10.1016/j.neurobiolaging.2016.02.009

Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. 1989. The Pittsburgh sleep quality index: A

new instrument for psychiatric practice and research. *Psychiatry Res* **28**:193–213.

doi:10.1016/0165-1781(89)90047-4

Carrier J, Viens I, Poirier G, Robillard R, Lafortune M, Vandewalle G, Martin N, Barakat M, Paquet J,

Filipini D. 2011. Sleep slow wave changes during the middle years of life. *Eur J Neurosci* **33**:758–

766. doi:10.1111/j.1460-9568.2010.07543.x

Chai X, Dage JL, Citron M. 2012. Constitutive secretion of tau protein by an unconventional mechanism.

Neurobiol Dis **48**:356–366. doi:10.1016/j.nbd.2012.05.021

Crimins JL, Rocher AB, Luebke JI. 2012. Electrophysiological changes precede morphological changes

to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy. *Acta*

Neuropathol **124**:777–95. doi:10.1007/s00401-012-1038-9

Dash MB, Douglas CL, Vyazovskiy V V., Cirelli C, Tononi G. 2009. Long-Term Homeostasis of Extracellular

Glutamate in the Rat Cerebral Cortex across Sleep and Waking States. *J Neurosci* **29**:620–629.

doi:10.1523/JNEUROSCI.5486-08.2009

DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE,

Wozniak DF, Rigo F, Bennett CF, Cirrito JR, Holtzman DM, Miller TM. 2013. Antisense Reduction

of Tau in Adult Mice Protects against Seizures. *J Neurosci* **33**:12887–12897.

doi:10.1523/JNEUROSCI.2107-13.2013

Dijk D-J, Landolt H-P. 2019. Sleep Physiology, Circadian Rhythms, Waking Performance and the

Development of Sleep-Wake TherapeuticsHandbook of Experimental Pharmacology. Springer,

Berlin, Heidelberg. pp. 1–41. doi:10.1007/164_2019_243

Dijk DJ, Czeisler C a. 1995. Contribution of the circadian pacemaker and the sleep homeostat to sleep

propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in

humans. *J Neurosci* **15**:3526–3538.

Dudbridge F. 2013. Power and Predictive Accuracy of Polygenic Risk Scores. *PLoS Genet* **9**:e1003348.

doi:10.1371/journal.pgen.1003348

Ertekin-Taner N. 2010. Genetics of Alzheimer disease in the pre- and post-GWAS era. *Alzheimer's Res*

Ther. doi:10.1186/alzrt26

Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, Badarinarayan N, Morgan K,

Passmore P, Holmes C, Powell J, Brayne C, Gill M, Mead S, Goate A, Cruchaga C, Lambert JC, Van

Duijn C, Maier W, Ramirez A, Holmans P, Jones L, Hardy J, Seshadri S, Schellenberg GD, Amouyel

P, Williams J. 2015. Common polygenic variation enhances risk prediction for Alzheimer's disease.

Brain **138**:3673–3684. doi:10.1093/brain/awv268

Ettore E, Bakardjian H, Solé M, Levy Nogueira M, Habert M-O, Gabelle A, Dubois B, Robert P, David R.

2019. Relationships between objectives sleep parameters and brain amyloid load in subjects at

risk to Alzheimer's disease: the INSIGHT-preAD Study. *Sleep*. doi:10.1093/sleep/zsz137

Euesden J, Lewis CM, O'Reilly PF. 2015. PRSice: Polygenic Risk Score software. *Bioinformatics* **31**:1466–

8. doi:10.1093/bioinformatics/btu848

Fein JA, Sokolow S, Miller CA, Vinters H V, Yang F, Cole GM, Gylys KH. 2008. Co-localization of amyloid

beta and tau pathology in Alzheimer's disease synaptosomes. *Am J Pathol* **172**:1683–92.

doi:10.2353/ajpath.2008.070829

Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. 2006. Role

of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry* **63**:168–174.

doi:10.1001/archpsyc.63.2.168

Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. 2019. Polygenic prediction via Bayesian regression and

continuous shrinkage priors. *Nat Commun* **10**:1776. doi:10.1038/s41467-019-09718-5

Hall AM, Throesch BT, Buckingham SC, Markwardt SJ, Peng Y, Wang Q, Hoffman DA, Roberson ED.

2015. Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of

Alzheimer's disease. *J Neurosci* **35**:6221–6230. doi:10.1523/JNEUROSCI.2552-14.2015

Hammad G, Reyt M. 2019. ghammad/pyActigraphy: Actigraphy made simple!

doi:10.5281/ZENODO.2537921

Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, Scheidegger M, Berthold T, Gomez-

Mancilla B, Seifritz E, Landolt HP. 2013. Increased metabotropic glutamate receptor subtype 5

availability in human brain after one night without sleep. *Biol Psychiatry* **73**:161–168.

doi:10.1016/j.biopsych.2012.07.030

Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin SG, Pautler RG, Botas J, Noebels JL. 2013.

Tau Loss Attenuates Neuronal Network Hyperexcitability in Mouse and Drosophila Genetic

Models of Epilepsy. *J Neurosci* **33**:1651–1659. doi:10.1523/jneurosci.3191-12.2013

Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller

PM, Lucey BP, Holtzman DM. 2019. The sleep-wake cycle regulates brain interstitial fluid tau in

mice and CSF tau in humans. *Science (80-)* eaav2546. doi:10.1126/science.aav2546

Horne JA, Ostberg O. 1976. A self-assessment questionnaire to determine morningness-eveningness

in human circadian rhythms. *Int J Chronobiol* **4**:97–110.

Huber R, Mäki H, Rosanova M, Casarotto S, Canali P, Casali AG, Tononi G, Massimini M. 2013. Human

cortical   excitability   increases   with   time   awake.   *Cereb   Cortex*   **23**:332–338.

doi:10.1093/cercor/bhs014

Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen

F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers

E, Snyder HM, Sperling R, Elliott C, Masliah E, Ryan L, Silverberg N. 2018. NIA-AA Research

Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's Dement* **14**:535–

562. doi:10.1016/j.jalz.2018.02.018

John, Raven J. 2003. Raven Progressive MatricesHandbook of Nonverbal Assessment. Boston, MA:

Springer US. pp. 223–237. doi:10.1007/978-1-4615-0153-4_11

Johns MW. 1991. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale.

Sleep **14**:540–545. doi:10.1016/j.sleep.2007.08.004

Ju Y-ES, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM,

Claassen JAHR, Holtzman DM. 2017. Slow wave sleep disruption increases cerebrospinal fluid

amyloid-β levels. *Brain* **140**:2104–2111. doi:10.1093/brain/awx148

Klerman EB, Dijk DJ. 2005. Interindividual variation in sleep duration and its association with sleep debt

in young adults. *Sleep* **28**:1253–1259. doi:10.1093/sleep/28.10.1253

Lim ASP, Kowgier M, Yu L, Buchman AS, Bennett DA. 2013. Sleep Fragmentation and the Risk of Incident

Alzheimer's Disease and Cognitive Decline in Older Persons. *Sleep* **36**:1027–1032.

doi:10.5665/sleep.2802

Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L,

Xiong C, Morris JC, Benzinger TLS, Holtzman DM. 2019. Reduced non–rapid eye movement sleep

is associated with tau pathology in early Alzheimer's disease. *Sci Transl Med* **11**:eaau6550.

doi:10.1126/SCITRANSLMED.AAU6550

Ly JQM, Gaggioni G, Chellappa SL, Papachilleos S, Brzozowski A, Borsu C, Rosanova M, Sarasso S,

Middleton B, Luxen A, Archer SN, Phillips C, Dijk D-J, Maquet P, Massimini M, Vandewalle G. 2016.

Circadian regulation of human cortical excitability. *Nat Commun* **7**:11828.

doi:10.1038/ncomms11828

Mander BA, Marks SM, Vogel JW, Rao V, Lu B, Saletin JM, Ancoli-Israel S, Jagust WJ, Walker MP. 2015.

β-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory

consolidation. *Nat Neurosci* **18**:1051–1057. doi:10.1038/nn.4035

Marden JR, Mayeda ER, Walter S, Vivot A, Tchetgen EJT, Kawachi I, Glymour MM. 2016. Using an

Alzheimer disease polygenic risk score to predict memory decline in black and white Americans

over 14 years of follow-up. *Alzheimer Dis Assoc Disord* **30**:195–202.

doi:10.1097/WAD.0000000000000137

Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, Davies G, Ritchie CW, Gale CR, Starr

JM, Goate AM, Porteous DJ, Yang J, Evans KL, Deary IJ, Wray NR, Visscher PM. 2018. GWAS on

family history of Alzheimer's disease. *Transl Psychiatry* **8**:99. doi:10.1038/s41398-018-0150-6

Martiskainen H, Helisalmi S, Viswanathan J, Kurki M, Hall A, Herukka SK, Sarajärvi T, Natunen T,

Kurkinen KMA, Huovinen J, Mäkinen P, Laitinen M, Koivisto AM, Mattila KM, Lehtimäki T, Remes

AM, Leinonen V, Haapasalo A, Soininen H, Hiltunen M. 2015. Effects of Alzheimer's disease-

associated risk loci on cerebrospinal fluid biomarkers and disease progression: A polygenic risk

score approach. *J Alzheimer's Dis* **43**:565–573. doi:10.3233/JAD-140777

Mather M, Harley CW. 2016. The Locus Coeruleus: Essential for Maintaining Cognitive Function and

the Aging Brain. *Trends Cogn Sci* **20**:214–26. doi:10.1016/j.tics.2016.01.001

Mondragón-Rodríguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, Boehm J,

Mondragon-Rodriguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, Boehm

J, Mondragón-Rodríguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, Boehm

J. 2012. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-

D-aspartate receptor-dependent tau phosphorylation. *J Biol Chem* **287**:32040–32053.

doi:10.1074/jbc.M112.401240

Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, Sabuncu MR. 2016.

Polygenic risk of Alzheimer disease is associated with early- and late-life processes. *Neurology*

87:481–488. doi:10.1212/WNL.0000000000002922

Musiek ES, Holtzman DM. 2015. Three dimensions of the amyloid hypothesis: Time, space and

"wingmen." *Nat Neurosci*. doi:10.1038/nn.4018

Nilsen LH, Rae C, Ittner LM, Götz J, Sonnewald U. 2013. Glutamate metabolism is impaired in transgenic

mice with tau hyperphosphorylation. *J Cereb Blood Flow Metab* **33**:684–91.

doi:10.1038/jcbfm.2012.212

Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. 2014. Potential for primary prevention of

Alzheimer's disease: An analysis of population-based data. *Lancet Neurol* **13**:788–794.

doi:10.1016/S1474-4422(14)70136-X

Oddo S, Caccamo A, Shepherd JD, Murphy MPP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari

Y, LaFerla FM. 2003. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles.

Neuron **39**:409–421. doi:10.1016/S0896-6273(03)00434-3

Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen J a HR. 2014. Effect of 1 Night of Total

Sleep Deprivation on Cerebrospinal Fluid β-Amyloid 42 in Healthy Middle-Aged Men: A

Randomized Clinical Trial. *JAMA Neurol* **71**:971–977. doi:10.1001/jamaneurol.2014.1173

Pase MP, Himali JJ, Grima NA, Beiser AS, Satizabal CL, Aparicio HJ, Thomas RJ, Gottlieb DJ, Auerbach

SH, Seshadri S. 2017. Sleep architecture and the risk of incident dementia in the community.

Neurology **89**:10.1212/WNL.000000000004373. doi:10.1212/WNL.000000000004373

Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley

KJ, Spires-Jones TL, Hyman BT. 2014. Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. *Acta Neuropathol* **127**:257–270. doi:10.1007/s00401-013-1215-5

Pooler AM, Noble W, Hanger DP. 2014. A role for tau at the synapse in Alzheimer's disease pathogenesis. *Neuropharmacology* **76**:1–8. doi:10.1016/j.neuropharm.2013.09.018

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, Sham PC. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**:559–75. doi:10.1086/519795

Roh JH, Huang Y, Bero a. W, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. 2012. Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of β-Amyloid in Mice with Alzheimer's Disease Pathology. *Sci Transl Med* **4**:150ra122-150ra122. doi:10.1126/scitranslmed.3004291

Sabuncu MR, Buckner RL, Smoller JW, Lee PH, Fischl B, Sperling RA. 2012. The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. *Cereb Cortex* **22**:2653–2661. doi:10.1093/cercor/bhr348

Santoro ML, Ota V, de Jong S, Noto C, Spindola LM, Talarico F, Gouvea E, Lee SH, Moretti P, Curtis C, Patel H, Newhouse S, Carvalho CM, Gadelha A, Cordeiro Q, Bressan RA, Belangero SI, Breen G. 2018. Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort. *Transl Psychiatry* **8**:174. doi:10.1038/s41398-018-0230-7

Scammell TE, Arrigoni E, Lipton JO. 2017. Neural Circuitry of Wakefulness and Sleep. *Neuron*. doi:10.1016/j.neuron.2017.01.014

Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. 2016. Alzheimer's disease. *Lancet* **388**:505–517. doi:10.1016/S0140-6736(15)01124-1

Schmidt C, Peigneux P, Cajochen C. 2012. Age-related changes in sleep and circadian rhythms: Impact on cognitive performance and underlying neuroanatomical networks. *Front Neurol* **JUL**:118. doi:10.3389/fneur.2012.00118

Schultz MK, Gentzel R, Usenovic M, Gretzula C, Ware C, Parmentier-Batteur S, Schachter JB, Zariwala HA. 2018. Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice. *Neurobiol Dis* **118**:161–176. doi:10.1016/j.nbd.2018.07.003

Skorucak J, Arbon EL, Dijk D-J, Achermann P. 2018. Response to chronic sleep restriction, extension, and total sleep deprivation in humans: adaptation or preserved sleep homeostasis? *Sleep* 1–27. doi:10.1093/ntr/ntx198/4104547/Differences-in-adolescent-e-cigarette-and

Sleegers K, Bettens K, De Roeck A, Van Cauwenberghe C, Cuyvers E, Verheijen J, Struyfs H, Van Dongen J, Vermeulen S, Engelborghs S, Vandenbulcke M, Vandenberghe R, De Deyn PP, Van Broeckhoven C, BELNEU consortium. 2015. A 22-single nucleotide polymorphism Alzheimer's disease risk score

correlates with family history, onset age, and cerebrospinal fluid Aβ42. *Alzheimers Dement*

11:1452–60. doi:10.1016/j.jalz.2015.02.013

Steriade M, Amzica F. 1998. Slow sleep oscillation, rhythmic K-complexes, and their paroxysmal

developments. *J Sleep Res* **7**:30–35. doi:10.1046/j.1365-2869.7.s1.4.x

Svetnik V, Snyder ES, Ma J, Tao P, Lines C, Herring WJ. 2017. EEG spectral analysis of NREM sleep in a

large sample of patients with insomnia and good sleepers: effects of age, sex and part of the

night. *J Sleep Res* **26**:92–104. doi:10.1111/jsr.12448

Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G,

Mandelkow E, D'Hooge R, Alzheimer C, Mandelkow E-M. 2011. Tau-induced defects in synaptic

plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau

mutant. *J Neurosci* **31**:2511–25. doi:10.1523/JNEUROSCI.5245-10.2011

Thal D, Rüb U, Orantes M, Braak H. 2002. Phases of A beta-deposition in the human brain and its

relevance for the development af AD. *Neurology* **58**:1791–1800.

Tononi G, Cirelli C. 2014. Sleep and the Price of Plasticity: From Synaptic and Cellular Homeostasis to

Memory Consolidation and Integration. *Neuron* **81**:12–34. doi:10.1016/j.neuron.2013.12.025

Van der Jeugd A, Hochgräfe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun

D, D'Hooge R, Mandelkow E-M, Jochen A, Van der Jeugd A, Hochgräfe K, Ahmed T, Decker JM,

Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D'Hooge R, Mandelkow E-M, Jochen A. 2012.

Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human

Tau. *Acta Neuropathol* **123**:787–805. doi:10.1007/s00401-012-0987-3

Van Egroo M, Narbutas J, Chylinski D, Villar González P, Maquet P, Salmon E, Bastin C, Collette F,

Vandewalle G. 2019. Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer's

disease. *Sleep* **42**. doi:10.1093/sleep/zsz017

Viola AU, Archer SN, James LMM, Groeger JA, Lo JCY, Skene DJ, von Schantz M, Dijk DJ. 2007. PER3

Polymorphism Predicts Sleep Structure and Waking Performance. *Curr Biol* **17**:613–618.

doi:10.1016/j.cub.2007.01.073

Wallant DC t., Muto V, Gaggioni G, Jaspar M, Chellappa SL, Meyer C, Vandewalle G, Maquet P, Phillips

C. 2016. Automatic artifacts and arousals detection in whole-night sleep EEG recordings. *J

Neurosci Methods* **258**:124–133. doi:10.1016/j.jneumeth.2015.11.005

Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgräfe K, Mandelkow

E-M, Holtzman DM. 2014. Neuronal activity regulates extracellular tau in vivo. *J Exp Med*

211:387–393. doi:10.1084/jem.20131685

Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, Frayling TM, Hirschhorn J, Yang J,

Visscher PM. 2018. Meta-analysis of genome-wide association studies for height and body mass

index in ~700000 individuals of European ancestry. *Hum Mol Genet*. doi:10.1093/hmg/ddy271

Figures and Tables

Figure 1: Overview of the protocol.

Following 3 weeks of regular sleep at habitual times, 363 healthy young men aged ~22 y
complete a 7-day protocol (displayed for a participant sleeping from 11PM to 7PM).
Adaptation/screening and baseline nights were scheduled at habitual sleep-wake times.
Extension nights consisted of a 12h sleep opportunity centred around habitual sleep mid-
point. Nap consisted of an afternoon 4h sleep opportunity. The "Before" (sleep deprivation)
and recovery nights (from sleep deprivation) consisted of an 8h and 12h sleep opportunity
respectively, all starting at habitual sleep time. Following the "before" night, volunteers
completed a 40h sleep deprivation protocol under strictly controlled constant routine
conditions in dim light. Sleep periods included in the current analyses are in bold and italic.

Figure 2: Associations between Polygenic Risk Score (PRS) for AD and baseline night sleep metrics.

A. Statistical outcomes of GLMs with five sleep metrics of interest vs. AD PRS from conservative ($p < 5 \times 10^{-8}$) p-value threshold to using all SNPs. GLMs are corrected for age, BMI and total sleep time (TST). Negative log transformation of p-values of the associations are presented on the vertical axis. Horizontal lines in A and D indicate different p-values thresholds: light blue = .05 (uncorrected); orange= .01 (corrected for 5 sleep metrics); red = 0.00125 (experiment-wise correction; see methods).

SOL: sleep onset latency; WASO: wake time after sleep onset; DUR_REM: duration of REM sleep; arousal: hourly rate of micro-arousal during sleep; SWE: slow wave energy in NREM sleep (0.5-4Hz)

B. Positive association between SWE during baseline night and AD PRS including All SNPs. Spearman correlation r is reported for completeness (r = .12, p = .02), refer to main text Table S2 for statistical outputs of GLMs.

C. Negative association between SOL during baseline night and AD PRS for p < 0.3. Spearman correlation r is reported for completeness (r = -.11, p = .03), refer to main text Table S2 for statistical outputs of GLMs.

D. GLMs including SWE separated in the slower (SO-SWE; 0.5-1Hz) and faster (FO-SWE; 1.25-4Hz) frequency range from conservative p-value thresholds to using all SNPs. Horizontal blue line indicate p = 0.05 significance level. GLMs are corrected for age, BMI and TST. Refer to main text Table S3 for statistical outputs of GLMs.

Figure 3: Associations between Polygenic Risk Score (PRS) for AD and slow wave energy (SWE) during recovery and extension nights and with SWE rebound.

A. Statistical outcomes of GLMs with SWE (0.5-4Hz) in the recovery (REC) and extension (EXT) nights and with SWE rebound (REC/BAS) vs. AD PRS from conservative ($p < 5x10^{-8}$) to inclusive ($p < 1$) p-value level and using all SNPs. SWE rebound consist in the ratio between SWE in the first hour of sleep of recovery and baseline nights. GLMs are corrected for age and BMI, and TST for REC and EXT. Negative log transformation of p-values of the associations are presented on the vertical axis. Horizontal lines indicate different p-values thresholds: light blue = .05 (uncorrected); red = 0.00625 (experiment-wise correction; see methods).

B. Positive association between SWE during recovery night and AD PRS at $p < 1$. Spearman correlation r is reported for completeness (r = .01, p = .06), srefer to main text Table S4 for statistical outputs of GLMs.

C. Positive association between SWE during recovery and SWE rebound (SWE REC/BAS): Spearman correlation r = .36, p < .001.

904 **Figure 4: Associations between Polygenic Risk Score (PRS) for AD and non-EEG sleep metrics.**
905

A. Statistical outcomes of GLMs with actimetry-assessed sleep fragmentation (kRA), subjective
sleep quality (Sleep-qual) and subjective daytime sleepiness (Day-sleepiness) vs. AD PRS from
conservative ($p < 5 \times 10^{-8}$) to inclusive ($p < 1$) p-value thresholds and using all SNPs. GLMs are
corrected for age and BMI. Negative log transformation of p-values of the associations are
presented on the vertical axis. Horizontal lines indicate different p-values: light blue = .05
(uncorrected); orange= .016 (corrected for 3 sleep metrics); red = 0.002 (experiment-wise
correction).
B. Positive association between subjective daytime sleepiness and AD PRS at $p < 0.05$. Linear
regression line shown for display purposes only; refer to main text and Table S5 for statistical
outputs of GLMs.

Table 1. Sample characteristics (mean ± SD).

N	363
Sex	Men
Ethnicity	Caucasian
Age (y)	22.10 ± 2.73
Height (cm)	180.39 ± 6.70
Body mass index (BMI) (kg m^{-2})	22.15 ± 2.31
IQ	123.88 ± 11.14
Education (y)	13.33 ± 1.60
Mood	3.00 ± 3.48
Sleep quality	3.46 ± 1.76
Daytime sleepiness	5.94 ± 3.54
Chronotype	50.11 ± 8.25
Rest-activity Fragmentation (a.u.)	0.10 ± 0.03
Baseline sleep duration (min)	451 ± 41

Mood was estimated by the 21-item Beck Depression Inventory II (Beck et al., 1988), sleep quality by the Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989); daytime sleepiness by the Epworth Sleepiness Scale (ESS)(Johns, 1991); chronotype by the Horne-Östberg questionnaire (Horne and Ostberg, 1976). IQ was estimated using Raven Progressive Matrices (John and Raven, 2003). Rest fragmentation (arbitrary units, a.u.) was estimated as the probability of transition from rest to activity during estimated sleep based on actigraphy data from the 3 weeks of imposed regular sleep (Hammad and Reyt, 2019; Lim et al., 2013).